"10.1371_journal.pone.0064961","plos one","2013-06-10T00:00:00Z","Ana de la Cueva; Ana Ramírez de Molina; Néstor Álvarez-Ayerza; Ma Angeles Ramos; Arancha Cebrián; Teresa Gómez del Pulgar; Juan Carlos Lacal","Traslational Oncology Unit, Instituto de Investigaciones Biomédicas, CSIC, Madrid, Spain; Instituto de Investigación Sanitaria IdiPAZ, Madrid, Spain","Conceived and designed the experiments: ARDM JCL TGDP AC. Performed the experiments: ADLC ARDM NAA MAR. Analyzed the data: ADLC ARDM JCL TGDP AC. Wrote the paper: ADLC ARDM TGDP AC JCL.","Juan Carlos Lacal is a founder of TCD Pharma and a member of its scientific advisory board but not an employee of the company. TCD Pharma is developing the compound TCD717, a ChoKα inhibitor, that is currently in Phase I clinical trials. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2013","06","Ana de la Cueva","ADLC",7,TRUE,4,4,5,5,TRUE,TRUE,TRUE,1,"3",FALSE
